Understanding how SETDB1 affects lung cancer progression
Dissecting the Mechanism of SETDB1 and its K867 Monoubiquitination in Lung Cancer Progression
This study is looking at a protein called SETDB1 to see how it affects the growth of non-small cell lung cancer, with the hope of finding new treatment options that could help patients with certain lung cancer mutations.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-10891407 on NIH RePORTER |
What this research studies
This research investigates the role of SETDB1, a key protein involved in modifying DNA, in the progression of non-small cell lung cancer (NSCLC). The study focuses on how SETDB1's modification of histones can influence cancer growth and how this may lead to new treatment strategies. By examining the mechanisms behind SETDB1's action, researchers aim to identify potential targets for therapies that could improve outcomes for patients with specific lung cancer mutations. The approach combines molecular biology techniques with cancer biology to uncover critical insights into tumor behavior.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer, especially those with KRAS mutations.
Not a fit: Patients with lung cancer types that do not involve KRAS mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for patients with lung cancer, particularly those with KRAS mutations.
How similar studies have performed: Other research has shown promising results in targeting epigenetic mechanisms in cancer, suggesting that this approach could be effective.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Fang, Jia — Roswell Park Cancer Institute Corp
- Study coordinator: Fang, Jia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.